STORM Therapeutics publishes data in Cancer Discovery showing induction of anti-tumour immunity by METTL3 inhibition

Posted on by

Pre-clinical data strongly supports progression of a METTL3 inhibitor in an immuno-oncology setting STC-15 is the first molecule specifically targeting METTL3 to enter clinical development CAMBRIDGE, England, Aug. 8, 2023 /PRNewswire/ — STORM Therapeutics Ltd. (STORM), a clinical stage…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.